
AMRUTANJAN - Amrutanjan Health Care Limited Share Price
Pharmaceuticals & Biotechnology
Valuation | |
---|---|
Market Cap | 2.09 kCr |
Price/Earnings (Trailing) | 38.34 |
Price/Sales (Trailing) | 4.36 |
EV/EBITDA | 25.75 |
Price/Free Cashflow | 136.16 |
MarketCap/EBT | 28.21 |
Enterprise Value | 2.08 kCr |
Fundamentals | |
---|---|
Revenue (TTM) | 479.78 Cr |
Rev. Growth (Yr) | 11.7% |
Earnings (TTM) | 54.53 Cr |
Earnings Growth (Yr) | 80.1% |
Profitability | |
---|---|
Operating Margin | 15% |
EBT Margin | 15% |
Return on Equity | 16.7% |
Return on Assets | 12.94% |
Free Cashflow Yield | 0.73% |
Price to Sales Ratio
Revenue (Last 12 mths)
Net Income (Last 12 mths)
Growth & Returns | |
---|---|
Price Change 1W | -4.8% |
Price Change 1M | 4.9% |
Price Change 6M | 12% |
Price Change 1Y | -6% |
3Y Cumulative Return | 0.40% |
5Y Cumulative Return | 11.3% |
7Y Cumulative Return | 16.4% |
10Y Cumulative Return | 13% |
Cash Flow & Liquidity | |
---|---|
Cash Flow from Investing (TTM) | -30.97 Cr |
Cash Flow from Operations (TTM) | 50.9 Cr |
Cash Flow from Financing (TTM) | -13.49 Cr |
Cash & Equivalents | 10.16 Cr |
Free Cash Flow (TTM) | 15.35 Cr |
Free Cash Flow/Share (TTM) | 5.31 |
Balance Sheet | |
---|---|
Total Assets | 421.39 Cr |
Total Liabilities | 94.77 Cr |
Shareholder Equity | 326.61 Cr |
Current Assets | 290.67 Cr |
Current Liabilities | 84.58 Cr |
Net PPE | 47.73 Cr |
Inventory | 27.26 Cr |
Goodwill | 0.00 |
Capital Structure & Leverage | |
---|---|
Debt Ratio | 0.00 |
Debt/Equity | 0.00 |
Interest Coverage | 358.43 |
Interest/Cashflow Ops | 247.96 |
Dividend & Shareholder Returns | |
---|---|
Dividend/Share (TTM) | 4.6 |
Dividend Yield | 0.64% |
Shares Dilution (1Y) | 0.00% |
Shares Dilution (3Y) | -1.1% |
Summary of Latest Earnings Report from Amrutanjan Health Care
Summary of Amrutanjan Health Care's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated:
Last updated:
Revenue Breakdown
Analysis of Amrutanjan Health Care's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
No revenue data available.
Share Holdings
Understand Amrutanjan Health Care ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
Holding Pattern
Share Holding Details
Shareholder Name | Holding % |
---|---|
GOODHEALTH HOLDINGS PRIVATE LIMITED | 20.15% |
SAMBHUPRASAD SIVALENKA | 10.34% |
DSP SMALL CAP FUND | 5.07% |
RAMAA PRABHAKAR ARIKIREVULA | 4.74% |
SAMBHU PRASAD SIVALENKA | 3.6% |
CARNELIAN BHARAT AMRITKAAL FUND | 2.99% |
RAMALINGAM GANTI | 2.53% |
ICICI PRUDENTIAL FMCG FUND | 2.47% |
AMULYA KAMAKSHI PRIYA ARIKIREVULA | 2.13% |
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS | 1.34% |
DIPAK KANAYALAL SHAH | 1.09% |
CARNELIAN STRUCTURAL SHIFT FUND | 1.09% |
Overall Distribution
Distribution across major stakeholders
Ownership Distribution
Distribution across major institutional holders
Is Amrutanjan Health Care Better than it's peers?
Detailed comparison of Amrutanjan Health Care against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|---|
MARICO | Marico | 90.85 kCr | 11.67 kCr | -3.40% | - | 54.38 | 7.78 | - | - |
DABUR | Dabur India | 87.42 kCr | 13.18 kCr | -5.40% | -22.10% | 48.99 | 6.63 | - | - |
PGHH | Procter & Gamble Hygiene & Health Care | 46.14 kCr | 3.42 kCr | +8.60% | -13.40% | 61.72 | 13.5 | - | - |
EMAMILTD | Emami | 24.17 kCr | 3.89 kCr | -3.40% | -26.30% | 29.55 | 6.22 | - | - |
Sector Comparison: AMRUTANJAN vs Pharmaceuticals & Biotechnology
Comprehensive comparison against sector averages
Comparative Metrics
AMRUTANJAN metrics compared to Pharmaceuticals
Category | AMRUTANJAN | Pharmaceuticals |
---|---|---|
PE | 38.48 | 35.03 |
PS | 4.37 | 4.93 |
Growth | 7.9 % | 9 % |
Performance Comparison
AMRUTANJAN vs Pharmaceuticals (2021 - 2025)
- 1. AMRUTANJAN is NOT among the Top 10 largest companies in Pharmaceuticals.
- 2. The company holds a market share of 0.1% in Pharmaceuticals.
- 3. The company is growing at an average growth rate of other Pharmaceuticals companies.
Income Statement for Amrutanjan Health Care
Balance Sheet for Amrutanjan Health Care
Cash Flow for Amrutanjan Health Care
What does Amrutanjan Health Care Limited do?
Amrutanjan Health Care is a dynamic Pharmaceuticals company, recognized by its stock ticker, AMRUTANJAN, and boasting a market capitalization of Rs. 1,923 Crores.
The company specializes in manufacturing, supplying, and selling a variety of products including ayurvedic pain balms and women’s hygiene items. It operates through multiple segments: OTC Products, Beverages, and Others.
In the realm of pain management, Amrutanjan produces an array of products such as pain balms, roll-ons, back pain relief roll-ons, stick-on patches, body pain gels, and joint muscle sprays. For congestion management, the company offers cold rubs, cough syrups, nasal inhalers, and swas mints. Additionally, it provides sanitary napkins for women, along with corn caps, dental gels, hand sanitizers, and juice drinks marketed under the Fruitnik and Fruitnik Electro+ brands.
Amrutanjan Health Care also operates a pain management center and exports its products to regions such as the Middle East, Africa, and Southeast Asia.
Originally founded in 1893 and known as Amrutanjan Limited, it rebranded to Amrutanjan Health Care Limited in 2007. The company is headquartered in Chennai, India, and has reported a trailing 12-month revenue of Rs. 461.9 Crores.
Amrutanjan Health Care is profitable, with a profit of Rs. 49.3 Crores reported over the past four quarters. Over the last three years, the company has experienced a commendable revenue growth of 13.7%.
In terms of shareholder returns, Amrutanjan distributes dividends, offering a yield of 0.84% per year, with Rs. 5.6 paid out per share in the last 12 months.